At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.

We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, SUMAVEL™ DOSEPRO™ (sumatriptan injection) needle-free delivery system, enables subcutaneous delivery of sumatriptan without a needle for the treatment of acute migraine. We submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration, (FDA), for Sumavel DosePro in December 2007, and it was accepted for filing by the FDA in March 2008. SUMAVEL DOSEPRO is currently undergoing review by the FDA and, if approved, we intend to launch the product in the second half of 2009 with our own focused sales force and co-promotion partner in the US. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. This product candidate has completed Phase 2 clinical trials. We are seeking a co-development partner for the initiation of the Phase 3 clinical program.

SUMAVEL™ DOSEPRO^™

SUMAVEL DOSEPRO utilizes our proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan for the treatment of migraine and cluster headache. SUMAVEL DOSEPRO is a fast acting therapy that patients can self-administer in three easy steps. Click here to learn more.